Advancing Healthcare: From Testing to Treatment

BioSupply Trends Quarterly Fall 2015 Clinical Trials

On average, only 25 new experimental drugs were approved by the FDA’s Center for Drug Evaluation and Research (CDER) every year during the past decade. Taking more than 10 years to go from testing to treatment, the healing properties of these drugs help countless numbers of patients, sometimes providing life-changing and lifesaving results.

Addressing Declining Vaccination Rates

BioSupply Trends Quarterly Summer 2015 The Vaccine Gap

A “vaccination gap” has resulted in fewer children receiving the recommended immunizations, and diseases that were once considered all but eliminated are reemerging.

Safe Medicine: A Shared Responsibility

BioSupply Trends Quarterly Spring 2015 Safe Medicine

FFF Enterprises takes a “safety first” approach when it comes to business best practices for distributing fragile biologics and transport-sensitive vaccines.

Leading Innovation and Supply Chain Safety

As president and CEO of TraceLink,Inc., Shabbir Dahod leads a visionary team that helps companies meet the complex requirements of the Drug Supply Chain Security Act.

The Growth of the Plasma Market

BioSupply Trends Quarterly Winter 2015 MImmune Globulin

In this annual plasma-themed issue of BioSupply Trends Quarterly, we take a critical look at the current plasma market, especially issues of supply and demand.

Minimizing the Risks of Medicine

BioSupply Trends Quarterly Spring 2014 Safe Medicine

A deeper look at major risks in the healthcare industry, including lack of preventative care, inadequate care, adverse drug reactions and counterfeit drugs.